表紙
市場調查報告書

促進整體症狀前疾病模型研究的技術進步

Technological Advances Facilitating Research Across Preclinical Disease Models

出版商 Frost & Sullivan 商品編碼 949179
出版日期 內容資訊 英文 78 Pages
商品交期: 最快1-2個工作天內
價格
促進整體症狀前疾病模型研究的技術進步 Technological Advances Facilitating Research Across Preclinical Disease Models
出版日期: 2020年06月24日內容資訊: 英文 78 Pages
簡介

本報告重點介紹了可促進臨床前疾病模型研究的技術,包括目標技術的基準和路線圖,市場趨勢,功能和應用分析,利益相關者的活動,影響和行業計劃。它涵蓋投資環境和融資,行業發展和業務分析。

內容

第1章執行摘要

  • 研究重點
  • 調查範圍
  • 分析框架
  • 調查方法

第2章技術狀況和趨勢

  • 技術專長
  • 方法,策略,工具
  • 靶標,分子,生物學
  • 世界技術融合
  • 相鄰行業之間的轉化

第3章技術狀態審核和評估

  • 臨床前研究技術的新機遇
  • 促進科學技術發展
  • 藥物化學/平台化學技術
  • 類生物體,球體和3D自組織組織
  • 仿生傳感器和生物功能芯片(有機芯片)設備
  • 用於研究的動物模型
  • 生殖細胞基因編輯工具和乾細胞重編程
  • 光學,多模態和平移成像

第四章業務狀況與知識產權

  • 採用臨床前疾病模型的影響
  • 宏觀到微觀的視覺及其影響
  • 行業關鍵驅動力摘要
  • 行業主要問題摘要
  • 行業主要驅動因素和限制因素的摘要
  • 主要促進因素/抑制因素的映射
  • 技術轉讓的評估與認可
  • 在臨床前疾病模型中開放創新途徑

第5章技術雷達和智能解決方案

  • 技術成熟度和解釋
  • 利用技術協同效應的路線圖
  • 混合業務模式
  • 促進臨床前疾病模型的方法
  • 技術重塑價值鏈的協同效應
  • 臨床前技術的未來觀

第6章資金和投資狀況

  • 融資和投資模式與招聘
  • 資金重點
  • 臨床前研究基金趨勢
  • 按類型劃分的私人基金分佈
  • 按類型劃分的公共資金分配
  • 按地區劃分的公共和私人資金
  • 著名的公共和私人基金

第7章創新動態與產業演進

  • 未來主要行業趨勢
  • 臨床前領域的增長促進因素
  • 藥物發現中的行業動態
  • 該地區收養的可能性
  • 增長機會評估
  • 臨床前研究生態系統

第8章精選公司

  • 關注每個技術領域的公司
  • 按技術領域劃分的關鍵創新
  • 藥物化學/平台化學
  • 有機體,球體和3D自組織
  • 仿生傳感器和生物功能芯片(有機芯片)設備
  • 用於研究的動物模型
  • 生殖細胞基因編輯工具和乾細胞重編程
  • 光學,多模態和平移成像

第9章附錄A

第10章附錄B

目錄
Product Code: D98E

Bioengineering Innovations in Preclinical Research

The key focus of this research has been outlined as below:

  • 1. Technology benchmarking and roadmap, market trends, capabilities, and applications targeted: Build a robust strategy by defining the universe of preclinical disease models opportunities and setting key priorities
  • 2. Stakeholder activities, influence, industry initiatives: Evaluate opportunities by describing the main participants in the industry, analyzing potential outcomes and generating competitive intelligence
  • 3. Investment environment and funding support: Support execution by connecting specific strategies with milestones, targets, owners, and deadlines based in funding and investments
  • 4. Industry evolution and business analytics: Preclinical disease models overall industry evolution and business models

Table of Contents

1.0 Executive Summary

  • 1.1. Research Focus
  • 1.2. Research Scope
  • 1.3. Analysis Framework
  • 1.4. Research Methodology

2.0 Technology Landscape and Trends

  • 2.1. Technology Expertise
  • 2.2. Methods, Strategies and Tools
  • 2.3. Targets, Molecules and Biology
  • 2.4. Global Technology Convergence
  • 2.5. Translation from/to Adjacent Industries

3.0 Technology Status Review and Assessment

  • 3.1. Emerging Opportunities for Preclinical Research Technologies
  • 3.2. Enabling Science and Technology Developments
  • 3.3. Medicinal Chemistry and Platform Chemistry Technologies
  • 3.4. Organoids, Spheroids and 3D Self-Assembled Tissues
  • 3.5. Biomimetic Sensors and Organ-on-Chip Devices
  • 3.6. Animal Models Used in Research
  • 3.7. Germline Gene Editing Tools and Stem Cells Reprogramming
  • 3.8. Optical, Multimodality and Translational Imaging

4.0 Business Landscape and Intellectual Property

  • 4.1. Preclinical Disease Models Adoption Impact
  • 4.2. Macro to Micro Visioning and Implications
  • 4.3. Summary of Key Industry Drivers
  • 4.4. Summary of Key Industry Challenges
  • 4.5. Summary of Key Market Drivers and Restraints
  • 4.6. Mapping of Key Market Drivers and Restraints
  • 4.7. Technology Transfer Assessment and Perceptions
  • 4.8. Open Innovation Avenues in preclinical disease models

5.0 Technology Radar and Intelligent SOlutions

  • 5.1. Technology Maturity Level and Description
  • 5.2. Roadmap Tapping into Technology Synergy
  • 5.3. Business Model Hybridization
  • 5.4. Approaches Driving Preclinical Disease Models
  • 5.5. Technology Synergy Reshaping Value Chain
  • 5.6. Future Perspective of Preclinical Technology

6.0 Funding and Investment Landscape

  • 6.1. Funding and Investment Models and Adoption
  • 6.2. Funding Contribution Focus
  • 6.3. Preclinical Research Funding Trends
  • 6.4. Private Investment Distribution by Type
  • 6.5. Public Funding Distribution by Type
  • 6.6. Public and Private Funding by Region
  • 6.7. Public and Private Funding to Notice

7.0 INNOVATION DYNAMICS AND Industry Evolution

  • 7.1. Key Future Industry Trends
  • 7.2. Levers for Growth in the Preclinical Space
  • 7.3. Industry Dynamics in Drug Discovery
  • 7.4. Regional Adoption Potential
  • 7.5. Growth Opportunity Assessment
  • 7.6. Preclinical Research Ecosystem

8.0 Companies to Watch

  • 8.1. Companies to Watch per Technology Focus
  • 8.2. major Innovations per Technology Segment
  • 8.3. Medicinal Chemistry and Platform ChemistRy
  • 8.4. Organoids, Spheroids and 3D Self-assemblies
  • 8.5. Biomimetic Sensors and Organ-on-chip Devices
  • 8.6. Animal Models Used in Research
  • 8.7. Gene Editing and Stem Cells Reprogramming
  • 8.8. Optical, Multimodal Translational Imaging

9.0 Appendix A

  • 9.1. Key Industry Influencers
  • 9.2. Key Industry Innovators
  • 9.3. Key Industry Developers
  • 9.4. Key Industry Referents
  • 9.5. Key Industry Exemplars

10.0 Appendix B

  • 10.1. NEW DEVELOPMENT PARTNERSHIPS IN 2019-2020
  • 10.2. Collaboration agreements IN 2019-2020
  • 10.3. Licensing Deals IN 2019-2020
  • 10.4. Acquisitions and PARTNERSHIPS IN 2019-2020
  • 10.5. Additional collaborations IN 2019-2020
  • Legal Disclaimer